Recent approvals

Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need. Chemotherapies are widely used for the treatment of several types of cancer, including lymphomas. However, chemotherapies have some limitations, which reduces patient adherence toward the treatment.

Such factors have fuelled exhaustive research on target therapies such as PI3K inhibitors for the treatment of cancer. Several drugs have been approved, such as copanlisib (ALIQOPA) for the treatment of FL, in September 2017. Thus, recent approvals are expected to fuel the PI3K inhibitors market to grow at a CAGR of about 5% during the forecast period.

Reimbursement programs

The cost of PI3K inhibitors is usually high, owing to the complex manufacturing process. This has also had a negative impact on the PI3K inhibitors market for a long time. Therefore, various government bodies have started patient assistance programs to reduce the cost burden on patients and make these treatments available at an affordable price. Thus, the availability of reimbursement programs is expected to fuel the growth of the PI3K inhibitors market size during the forecast period.

Market Dynamics

The report also looks at factors such as recent approvals, strategic alliances, and special drug designations. However, low adoption of drugs, clinical trial failures, and stringent regulations may hamper the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Segment Coverage

The phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and other indications. This analysis also considers the sales of phosphoinositide 3-kinase inhibitors in Asia, Europe, North America, and RoW.

In 2018, the CLL segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high prevalence of CLL and FL and increasing new cases of cancer will play a significant role in the CLL segment to maintain its market position.

Competitive Landscape

With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphoinositide 3-kinase inhibitors manufacturers, that include:

• Bayer AG
• Gilead Sciences Inc.
• Novartis AG
• TG Therapeutics Inc.
• Verastem Inc.

Also, the phosphoinositide 3-kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

• Comparison by application
• CLL - Market size and forecast 2018-2023
• FL - Market size and forecast 2018-2023
• Other indications - Market size and forecast 2018-2023
• Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• RoW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

• Expansion of research indications
• Reimbursement programs
• Growing awareness about cancer

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Gilead Sciences Inc.
• Novartis AG
• TG Therapeutics Inc.
• Verastem Inc.

For more information about this report visit https://www.researchandmarkets.com/r/i4kgfs